Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Kaleido Biosciences Inc

(NASDAQ: KLDO)
Add to Portfolio
+0.17 (+1.86%)
as of Sep 16, 2019

Last 9.33
Change +0.17 (+1.86%)
Open 9.20
Prev. Close 9.16
Today's Range
9.16
9.43
52wk Range
6.23
19.00
Volume 34,758
Avg Volume 78,350
Sector Medical - Biomedical

Perfomance Comparison

Name Today 3-Month 1-Year
KLDO +1.86% +2.75% -34.43%
DJIA -0.52% +0.57% +3.53%
S&P 500 -0.31% +0.25% +3.20%

Key Statistics

Annual EPS N/A
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 277,440
Weighted Alpha -41.27
Standard Deviation +0.84
Profit Margin N/A
Beta N/A

Growth Rates

YTD -34.43%

Opinion

Sell Hold Buy

Recent Headlines

Kaleido Biosciences to Present at the Morgan Stanley

GlobeNewswire via COMTEX - Thu Aug 29, 08:00AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that management will part(full story)
MS: 44.75 (-0.41), KLDO: 9.33 (+0.17)

Kaleido Biosciences Announces Appointment of Theo

GlobeNewswire via COMTEX - Mon Jul 15, 08:00AM EDT
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that The(full story)
EVLO: 8.08 (+0.15), KLDO: 9.33 (+0.17)

Kaleido Biosciences Announces Closing of Initial

GlobeNewswire via COMTEX - Mon Mar 04, 04:22PM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today an(full story)
MS: 44.75 (-0.41), KLDO: 9.33 (+0.17)

Nasdaq Welcomes Kaleido Biosciences, Inc. (Nasdaq:

GlobeNewswire via COMTEX - Thu Feb 28, 11:30AM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health, (full story)
NDAQ: 99.28 (-0.24), KLDO: 9.33 (+0.17)

Kaleido Biosciences Announces Pricing of Initial

GlobeNewswire via COMTEX - Wed Feb 27, 07:27PM EST
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today an(full story)
MS: 44.75 (-0.41), KLDO: 9.33 (+0.17)